ClinicalTrials.gg
CompletedNCT02106845Updated Jun 7, 2019

Effect of Regorafenib on Digoxin and Rosuvastatin in Patients With Advanced Solid Malignant Tumors.

A Phase 1 interventional study of Digoxin and Rosuvastatin in Neoplasms, sponsored by Bayer. Completed at 5 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-06-07.

Sponsored by Bayer · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

Evaluate the effect of regorafenib on the pharmacokinetics of digoxin (P-gp substrate : P-glycoprotein) and rosuvastatin (BCRP substrate: Breast cancer resistant protein) by comparing their Area under time curve (AUC(0-24)) and maximum drug concentration (Cmax) on Day -7 and Cycle 1 or Cycle 2 Day 15 of regorafenib in cancer patients

02

Conditions studied

  • Neoplasms

Browse trials for

Keywords

  • Regorafenib
  • Probe substrates
  • Pharmacokinetics
  • Cancer
  • Safety
  • Advanced solid malignant tumors
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 42 is below the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The following criteria apply to ALL patients starting the study treatment:

    • Patients with confirmed, locally advanced or solid tumors to standard therapy or in whom regorafenib is considered a standard treatment.
    • Male or Female Caucasian patients >/= 18 years of age
    • Women of and men must agree to use adequate before entering the program until at least 8 weeks after the last study drug administration.
    • of at leat 12 weeks
    • (ECOG) Performance Status of 0 or 1
    • Adequate bone marrow and liver function
    • Estimated (CLcr) ≥ 30 mL/min as calculated using the Cockroft-Gault (C-G) equation.
    • Thyroid Stimulating Hormone(TSH) within normal ranges.
  • The following inclusion criteria apply to Group A (digoxin + regorafenib) patients ONLY:

    • Potassium, magnesium and calcium blood levels within normal range according to the local laboratory.
  • The following inclusion criteria apply to Group B (rosuvastatin + regorafenib) patients ONLY:

    • Signed genetic . Patients must be able to understand and willing to sign the written informed consent intended to screen for BCRP and OATP1B1 polymorphisms.

Exclusion criteria

  • For ALL patients
  • Major surgical procedure, open , or significant traumatic injury within 28 days before start of study medication.
  • Non-healing wound, skin ulcer, or bone fracture.
  • Ongoing or active infection.
  • Other anticancer treatment.
  • Patients unable to swallow oral medications
  • For Group A (digoxin + regorafenib):

    • Family history of sudden cardiac death.
  • For Group B (rosuvastatin + regorafenib):

    • Patients with porphyria.
    • Patients with intestinal or urinary obstructions.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    P-gp probe substrate(digoxin)+regorafenib

    Drug: Digoxin · Drug: Regorafenib (Stivarga, BAY73-4506)

  • Experimental
    Group B: BCRP probe substrate (rosuvastatin) + regorafenib

    Drug: Rosuvastatin · Drug: Regorafenib (Stivarga, BAY73-4506)

Interventions

  • DrugDigoxin

    Single dose of digoxin 0.5 mg (2 tablets 0.25 mg) orally without and with regorafenib

  • DrugRosuvastatin

    Single dose of rosuvastatin 5mg (1 tablet 5 mg) without and with regorafenib 160 mg q.d. (4 tablets 40 mg)

  • Once daily orally 160 mg (4 tablets 40 mg)

06

What researchers measure

Primary outcomes

  1. Area under the plasma concentration-time curve from time zero to 24 hours (AUC(0-24)) for Digoxin

    Time frame: On Pre-Cycle Day -7 and on Cycle 1 Day15 or Cycle 2 Day 15

  2. Maximum drug concentration (Cmax) in plasma for Digoxin

    Time frame: On Pre-Cycle Day -7 and on Cycle 1 Day15 or Cycle 2 Day 15

  3. Area under the plasma concentration-time curve from time zero to 24 hours (AUC(0-24)) for rosuvastatin

    Time frame: On Pre-Cycle Day -7 and on Cycle 1 Day15 or Cycle 2 Day 15

  4. Maximum drug concentration (Cmax) in plasma for rosuvastatin

    Time frame: On Pre-Cycle Day -7 and on Cycle 1 Day15 or Cycle 2 Day 15

Secondary outcomes

  1. Tumor Response following RECIST criteria

    Time frame: From first dose up to 3 months after end of treatment

  2. Number of participants with adverse events as a measure of safety and tolerability

    Time frame: Up to 30 days after last dose

  3. Number of participants with drug related adverse events as a measure of safety and tolerability

    Time frame: Up to 30 days after last dose

07

Study locations

5 sites
  • Freiburg, Baden-Württemberg 79106, Germany
  • Frankfurt, Hessen 60488, Germany
  • Herne, Nordrhein-Westfalen 44625, Germany
  • Budapest, 1083, Hungary
  • Budapest, 1122, Hungary
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2014 to primary completion in Apr 2015, 12 months.

Of 677 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 62. This study's 12 months is below that.

Counting every sponsor, half of 904 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2014
First posted
Apr 8, 2014
StartActual
Apr 22, 2014
Primary completionActual
Apr 27, 2015
CompletionActual
Jun 12, 2018
Last update
Jun 7, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 7, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02106845
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Apr 8, 2014
Start date
Apr 22, 2014
Primary completion
Apr 27, 2015
Completion
Jun 12, 2018
Last update
Jun 7, 2019

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Regorafenib

Start the discussion